Douglas Rhee, MD
Ophthalmology · Cleveland, OHNPI 1528042298
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $84,410 of the $137,714 with a category attached, or 61.3%. 19 manufacturers reported payments, led by Alcon Research LLC at 34.0% of the total. Reporting peaked in 2024 at $45,340 and has fallen 68.4% since, to $14,306 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $709.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$47K
- Aerie Pharmaceuticals, Inc.$42K
- Alcon$25K
- AbbVie$15K
- Merck$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- plus $3K from 13 others
Across 26 payments — averaging $12,608 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$185K
- AbbVie$114K
- Ocular Therapeutix, Inc.$23K
- Glaukos Corporation$6K
What the payments were for
- Consulting fees$84,41061%
- Speaking & faculty fees$29,86622%
- Travel & lodging$17,13012%
- Food & beverage$6,2145%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 28 | $46,816 |
| Aerie Pharmaceuticals, Inc. | 42 | $41,701 |
| Alcon | 50 | $25,291 |
| AbbVie(2 entities) | 41 | $14,868 |
| Merck | 6 | $3,200 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $2,655 |
| Ivantis, Inc | 4 | $2,340 |
| Oyster Point Pharma, Inc. | 1 | $204 |
| Apellis Pharmaceuticals, Inc. | 2 | $142 |
| Glaukos Corporation | 2 | $139 |
| Mallinckrodt Hospital Products Inc. | 1 | $73 |
| Sight Sciences, Inc. | 2 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $56 |
| Thea Pharma Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Novartis | 1 | $30 |
| Halozyme Inc | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$82,312
- Rhopressa$36,037
- Hydrus Microstent$22,022
- DURYSTA$5,923
- CyPass$3,420
- SIMBRINZA$3,240
- VYZULTA$2,610
- Hydrus$2,340
- XEN$1,134
- Voyager DSLT$284
- TYRVAYA$204
- Centurion$136
- Syfovre$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- LUMIGAN$104
How this compares
$137,714 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 288 | $148,831 |
| LumiganBimatoprost | 150 | $65,794 |
| RocklatanNetarsudil Mesylat/Latanoprost | 80 | $31,347 |
| CombiganBrimonidine Tartrate/Timolol | 75 | $29,232 |
| Alphagan PBrimonidine Tartrate | 67 | $27,461 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 94 | $18,638 |
| Travoprost | 82 | $12,792 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 680 | $12,628 |
| Difluprednate | 103 | $12,400 |
| Latanoprost | 1,469 | $11,496 |
| Brimonidine Tartrate | 551 | $11,104 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $8,213 |
| AzoptBrinzolamide | 18 | $8,103 |
| Prednisolone Acetate | 202 | $6,201 |
| Timolol Maleate | 362 | $4,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $41,701 | $180,178368 claims |
| AbbVieLumigan, Combigan, Alphagan P | $14,868 | $122,487292 claims |
| AlconSimbrinza, Azopt | $25,291 | $16,31654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cleveland
- Peter KaiserCleveland$1.5M
- Justis EhlersCleveland$639K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
- Yasha ModiCleveland$234K
- Faruk OrgeCleveland$158K
- Danny MammoCleveland$149K
- Jeffrey GosheCleveland$82K
- William DuppsCleveland$44K
- Shree KurupCleveland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.